Tioguanine
From Wikipedia, the free encyclopedia
Tioguanine
|
|
Systematic (IUPAC) name | |
2-amino-7H-purine-6-thiol | |
Identifiers | |
CAS number | 154-42-7 |
ATC code | L01BB03 |
PubChem | 2723601 |
DrugBank | APRD00290 |
Chemical data | |
Formula | C5H5N5S |
Mol. weight | 167.193 g/mol |
Pharmacokinetic data | |
Bioavailability | 30% (range 14% to 46%) |
Metabolism | Intracellular |
Half life | 80 minutes (range 25-240 minutes) |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | oral |
Tioguanine (INN), formerly Thioguanine (BAN), is a drug that is used in the treatment of cancer. It belongs to the family of drugs called antimetabolites. It is a guanine analog. Its principal use is in acute leukaemias and chronic myeloid leukaemia.
[edit] Pharmacology
As a guanine analogue, it is transformed inside the cell into to 6-thioguanilyic acid (TGMP) which, by pseudofeedback interference with purine biosynthesis, interferes with the synthesis of guanine nucleotides. Some of its activity may also be due to the incorporation of thioguanine nucleotides into both RNA and DNA, but the end result is inducing cell cycle arrest and apoptosis.